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Sparfloxacin and clinafloxacin were the most active 
agents against ciprofloxacin-susceptible E. faecium strains 
(Table 2) .  Pefloxacin, however, was the least active 
agent, yielding an MIC230 value of 16 nig/L. If, again, 
a breakpoint of 1 mg/L is applied, none of the strains 
was susceptible to pefloxacin. Norfloxacin and ofloxacin 
also showed very low activity against these strains. For 
ciprofloxacin-resistant E. faecium strains. all the quino- 
lones showed MIC5o values lower than those observed 
against ciprofloxacin-resistant E.faecu1is strains. In terms 
of MIC90 clinafloxacin was again the most active 
fluoroquinolone against ciprofloxacin-resistant E.jhecium 
strains, 42% and 51% of these strains were inhibited by 
1 mg/L of sparfloxacin and clinafloxacin, respectively. 
The high in vitro activity of clinafloxacin against 
enterococci has been described [6,7]. Nevertheless, the 
MICso values obtained in this study are greater than 
those obtained in previous studies, suggesting a slow 
decrease in the susceptibility of enterococci to this 
agent. The other new quinolones, levofloxacin, spar- 
floxacin and trovafloxacin, did not improve on the 
results obtained with clinafloxacin. 
In summary, clinafloxacin, and to a lesser extent 
sparfloxacin, levofloxacin and trovafloxacin, showed 
greater in vitro activity than the classical fluoro- 
quinolones against enterococci. Taking into account 
the few therapeutic alternatives for infections caused by 
rnultiresistant strains, further experimental studies will 
be needed to determine if these new fluoroquinolones 
will be useful in the treatment of serious enterococcal 
infections caused by strains resistant to other antibiotics. 
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Usefulness of delayed hypersensitivity skin tests in 
HIV infected patients 
Clin Microbiol Infecf 1997; 3: 499-500 
The demands on the health services by patients infected 
with type 1 human immunodeficiency virus (HIV-1) 
are increasing markedly. In Spain, past or present 
intravenous drug users account for a significant pro- 
portion of the total infected individuals [I]. Their visits 
to doctors are random and do not fit into defined 
patterns. 
In this context, it is extremely important to obtain 
objective data which may help in the evaluation of 
their serologic, diagnostic and clinical status. Delayed 
hypersensitivity skin tests provide a very important 
diagnostic tool for assessing cellular immunity and 
several authors have advocated their use in clinical 
practice at  the initial evaluation [2,3]. At the same time, 
lymphocyte CD4 counts have become widely accepted 
as an indicator when assigning a prophylactic or thera- 
peutic regimen and in establishing life-expectancy 
[4,5]. This indicator has gained universal currency with 
the publication of the latest C D C  criteria for staging 
and clinical categorization [6].  
The objective of the present work is to evaluate the 
response to a skin test consisting of five bacterial and 
two fungal antigens (Ag) in a sample of HIV-1 infected 
individuals at their first visit to the doctor and to 
establish its relation to the CD4 lymphocyte count. 
Between October 1985 and March 1993 we studied 
a total of 503 individuals with risk factors who presented 
for clinical evaluation at the University Clinical Hospital 
of Valladolid. Their average age was 29 k 7 years (range: 
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16-74) and 72% were males. Ninety-two per cent of 
these subjects had a history of past or present intra- 
venous drug use. A cutaneous skin test was performed 
in all the patients at  the beginning of the study with 
Multitest IMC (Institut MCrieux, Lyon), which in- 
cludes Clostridiurn tetani, Covynebactevium diphtheriae, 
Streptococcus group C, Mycobacterium tuberculosis, Proteus 
mirabilis, Candida albicans and Tvichophyton mentagro- 
phytes, and it was read 48-72 h later. We also obtained 
an absolute CD4 lymphocyte count on peripheral 
blood. The Multitest response was classified as ‘normal’ 
when there was frank response to more than two 
antigens, ‘partial’ if there was response to one or two 
antigens, and ‘anergic’ when no reactivity or reactivity 
below control level (glycerin) was found. The chi- 
squared statistical test was used for making com- 
parisons. 
Table 1 Relationship between cutaneous Multitest and 
CD4 lymphocyte count 
CD4 lymphocytes/mn3 
Response to 
cutaneous Multitest No. <200 2200 
is twofold. First, these patients are infrequent clinic 
attenders and also have difficult venous access; skin 
testing may partly help to overcome this difficulty. 
Second, there is a11 increasing problem of tuberculosis 
in these patients; multiple skin tests are helpful in 
assessing the value of Mantoux testing. One important 
difficulty remains: ensuring that the reading of the skin 
tests is homogeneous. Ideally, we should determine the 
inter-observer variation (K-COefflCient); more studies 
are necessary in order to control the information bias 
derived from the interpretation carried out by several 
observers. 
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NormaVPartial 329 20 309 
Anergic 174 21 153 
Total SO3 41 462 
Abnormal or partial responses to Multitest IMC 
were seen in 329 patients and 174 were anergic. Table 
1 shows these data categorized according to the total 
CD4 lymphocyte count. We found that in anergic 
patients the relative risk of having a CD4 count 
<200/mm3 was 1.985 (95% CI: 1.107-3.561, p<0.02). 
There was no significant difference in terms of CD4 
count between normal and partial responders. We 
chose this ‘cut-off according to CD4 cell category 
(subgroup 3) in the CDC classification. This important 
association (delayed hypersensitivity testing with CD4) 
should be clinically useful in HIV+ intravenous drug 
users, particularly in developing countries which do 
not have easy access to CD4 count monitoring. It 
seems clear that viral load is the most useful marker of 
disease progression. 
Our data are in line with those often found in 
clinical studies [3,7] and support the utilization of rapid 
tests in clinical practice. In our experience the cutaneous 
Multitest is a valuable alternative in the context of 
initial clinical evaluation, offering a good correlation 
with CD4 circulating levels, because of its low cost and 
easy application. In our practice with a large proportion 
of intravenous drug users who are HIV infected, the 
practical importance of delayed hypersensitivity testing 
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